Trial Profile
A Randomized Phase II Study to Evaluate the Efficacy and Safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in Patients With Recurrent and/or Metastatic, Androgen Receptor (AR) Expressing, Salivary Gland Cancer (SGCs)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Apr 2024
Price :
$35
*
At a glance
- Drugs Bicalutamide (Primary) ; Triptorelin (Primary) ; Carboplatin; Cisplatin; Doxorubicin; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Salivary gland cancer
- Focus Therapeutic Use
- 20 Apr 2024 This trial has been completed in Netherlands, according to European Clinical Trials Database record.
- 31 May 2023 Planned primary completion date changed from 31 Mar 2023 to 30 Jun 2023.
- 13 Mar 2023 Planned primary completion date changed from 24 Feb 2023 to 31 Mar 2023.